Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Horizon Pharma grants Mallinckrodt LLC US co-promote rights to Duexis; deal terminated

Executive Summary

Horizon Pharma Inc. (therapies for pain and inflammation) has granted Covidien Ltd.’s pharmaceutical subsidiary Mallinckrodt LLC US co-promotion rights to Duexis (ibuprofen and famotidine) through the end of 2014, with potential for the parties to extend the agreement.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register